GSK PLC-SPON ADR will close its vaccine manufacturing plant in Dresden, Germany, in the summer of 2027, putting 641 jobs at risk. The shutdown reflects falling demand for traditional egg-based flu shots globally. The move shifts the company's production focus entirely to its Canadian facility.
